Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma.

Nick LandmanDanielle HulsmanJitendra BadhaiJawahar KopparamJulian PuppeGaurav Kumar Pandey Maarten van Lohuizen

Published in: British journal of cancer (2024)

We demonstrated the efficacy of the combination of ATM and EZH2 inhibition against BAP1-deficient mesothelioma in preclinical models, indicating the potential of this combination as a novel treatment modality using BAP1 as a biomarker.

Keyphrases

dna damage
dna damage response
long non coding rna
long noncoding rna
bone marrow
cell therapy
combination therapy
replacement therapy